BRPI0506470A - produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento - Google Patents

produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento

Info

Publication number
BRPI0506470A
BRPI0506470A BRPI0506470-8A BRPI0506470A BRPI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A
Authority
BR
Brazil
Prior art keywords
helix
salt
treatment method
pharmaceutical composition
molecular compound
Prior art date
Application number
BRPI0506470-8A
Other languages
English (en)
Inventor
Fernand Labrie
Shankar Singh
Sylvain Gauthier
Yvon Frechette
Sylvain Chenard
Rock Breton
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of BRPI0506470A publication Critical patent/BRPI0506470A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"PRODUTOS FARMACêUTICOS ESTEROIDAL DIRECIONADO A HELIX 12, INCLUINDO COMPOSTO MOLECULAR DA FóRMULA OU SAL DO MESMO; COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO". Compostos possuindo a estrutura ou seus sais são usados para o tratamento ou redução da probabilidade de adquirir doenças que dependem de andrógeno, tais como, câncer de próstata, hiperplasia prostática benigna, sindrome ovariana policística, acne, hirsutismo, seborréia, alopecia androgênica e males da calvície. Eles podem ser formulados juntos com diluentes ou condutores aceitáveis farmacêuticamente ou por outro lado feitos em qualquer forma de dosagem farmacêutica. Alguns destes compostos possuindo tecido específico de atividade antiandrogênica podem ser usados para tratar ou reduzir o risco do desenvolvimento das doenças referentes à perda da estimulação androgênica. Combinações com outros agentes farmacêuticos ativos, são também revelados.
BRPI0506470-8A 2004-01-07 2005-01-06 produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento BRPI0506470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53512104P 2004-01-07 2004-01-07
PCT/CA2005/000011 WO2005066194A1 (en) 2004-01-07 2005-01-06 Helix 12 directed steroidal pharmaceutical products

Publications (1)

Publication Number Publication Date
BRPI0506470A true BRPI0506470A (pt) 2007-02-21

Family

ID=34749018

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506470-8A BRPI0506470A (pt) 2004-01-07 2005-01-06 produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento

Country Status (16)

Country Link
US (1) US9090651B2 (pt)
EP (1) EP1704161A4 (pt)
JP (1) JP4866740B2 (pt)
KR (2) KR101536701B1 (pt)
CN (2) CN102358750B (pt)
AU (2) AU2005203922A1 (pt)
BR (1) BRPI0506470A (pt)
CA (1) CA2551737C (pt)
HK (1) HK1167657A1 (pt)
IL (1) IL176538A0 (pt)
MY (1) MY157898A (pt)
NO (1) NO20063564L (pt)
RU (1) RU2397176C2 (pt)
TW (1) TWI383993B (pt)
WO (1) WO2005066194A1 (pt)
ZA (1) ZA200605242B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551737C (en) 2004-01-07 2009-11-10 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
GB0428128D0 (en) * 2004-12-22 2005-01-26 Avecia Ltd Process
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
GB2461037A (en) * 2008-06-17 2009-12-23 Elias Bouras A method of treating alopecia using a composition comprising a cardiac glycoside
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
CN102746360B (zh) * 2012-06-19 2014-07-02 广西民族大学 四种喜树碱-甾体缀合物的合成及其应用
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN105237606B (zh) * 2014-07-11 2018-08-24 上海创诺制药有限公司 一种用于合成去氧孕烯的中间体及其制备方法和应用
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
EP4066827A1 (en) 2016-06-22 2022-10-05 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
CN108822175B (zh) * 2018-04-26 2021-01-05 昆明理工大学 3,16-雄甾烯二酮类化合物及其应用
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0254341B1 (en) * 1986-07-23 1990-01-03 Akzo N.V. Novel 18-phenyloestrane derivatives
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1995018821A2 (en) * 1994-01-06 1995-07-13 Sri International Novel antiandrogenic agents and related pharmaceutical compositions and methods of use
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
EP1094798A2 (en) 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
AU2001288213B2 (en) 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
JP3908162B2 (ja) * 2000-06-30 2007-04-25 中外製薬株式会社 新規な抗アンドロゲン剤
NZ530810A (en) 2001-09-06 2006-05-26 Schering Corp 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60309667D1 (de) * 2002-02-15 2006-12-28 Endorech Inc Biphenylderivate und ihre verwendung als antiandrogene
JP4516316B2 (ja) * 2002-03-13 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレーターとしてのフッ化４−アザステロイド誘導体
EP1501512A4 (en) * 2002-04-30 2009-11-18 Merck & Co Inc 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
CA2551737C (en) 2004-01-07 2009-11-10 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Also Published As

Publication number Publication date
EP1704161A1 (en) 2006-09-27
RU2397176C2 (ru) 2010-08-20
AU2009202038A1 (en) 2009-06-11
KR101536701B1 (ko) 2015-07-14
MY157898A (en) 2016-08-15
IL176538A0 (en) 2006-10-05
CA2551737A1 (en) 2005-07-21
CA2551737C (en) 2009-11-10
HK1167657A1 (zh) 2012-12-07
RU2006128574A (ru) 2008-02-20
US9090651B2 (en) 2015-07-28
JP4866740B2 (ja) 2012-02-01
WO2005066194A1 (en) 2005-07-21
CN102358750A (zh) 2012-02-22
NO20063564L (no) 2006-10-09
AU2009202038A2 (en) 2009-08-06
CN102358750B (zh) 2015-11-25
KR20130124576A (ko) 2013-11-14
CN1930181A (zh) 2007-03-14
JP2007519635A (ja) 2007-07-19
TWI383993B (zh) 2013-02-01
US20050250749A1 (en) 2005-11-10
TW200530264A (en) 2005-09-16
AU2005203922A1 (en) 2005-07-21
KR20070003851A (ko) 2007-01-05
EP1704161A4 (en) 2011-06-08
ZA200605242B (en) 2007-10-31

Similar Documents

Publication Publication Date Title
BRPI0506470A (pt) produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento
BRPI0611828B8 (pt) compostos antiandrogênios não-esteroidais direcionados à hélice 12 e composição farmacêutica compreendendo os referidos compostos
Singh et al. Androgen receptor antagonists (antiandrogens) structure-activity relationships
BR9908592A (pt) Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
BR9913903A (pt) Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
DE69034035D1 (de) Methode zur behandlung androgenbedingter krankheiten
KR910004651A (ko) 5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
RU94046057A (ru) Ингибиторы активности тестостерон 5 альфа -редуктазы, фармкомпозиция, способ подавления активности, тестостерон 5 альфа -редуктазы
ATE333885T1 (de) Verwendung von sulodexid zur behandlung von reizdarm
ATE280756T1 (de) Substituierte benzolverbindungen als antiproliferative mittel
BRPI0817804A8 (pt) Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
AR021757A1 (es) Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
BRPI0514187A (pt) composto, e, droga preventiva ou uma droga terapêutica
ES2300323T3 (es) Quimioterapia combinada.
DK1194109T3 (da) Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
NZ327041A (en) 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
Nowak-Sliwinska et al. Angiostasis-induced vascular normalization can improve photodynamic therapy
DE69911017D1 (en) Arylsulfonanilid-phosphate
BR0107954A (pt) Inibidores duplos de sìntese de éster de colesterol e éster de cera para distúrbios de glândula sebácea

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]